Vaxcyte at guggenheim healthcare conference: strong vaccine data, long road

On 10 November 2026, Vaxcyte presented a positive update on its vaccine pipeline at the 3rd Annual Guggenheim Healthcare Innovation Conference. The company's 31-valent pneumococcal conjugate vaccine, VAX-31, showcased strong Phase III results across serotypes, achieving 11-for-11 in primary endpoints compared to existing vaccines PCV20 and PCV21.

Vaxcyte aims to submit a Biologics License Application for VAX-31 in the first half of 2028, pending further clinical trials, regulatory, and manufacturing work. The company's cash balance stands at approximately $3.4 billion, fully funding the anticipated adult launch, with shares trading at $66.72, giving the company a market capitalization of $10.6 billion.

Despite its progress, Vaxcyte faces a lengthy journey to approval, requiring three major clinical studies, manufacturing consistency work, and additional CMC activities.